Immunotherapy
| PembrolizumabFirst-line (advanced disease) FDA-approved for this cancer. | — | Guideline option | |
| pembrolizumabDNA MMR (mismatch repair) deficiency, MSI-high or high TMB FDA-approved for this cancer. | — | Guideline option |
Bladder Cancer: treatment map
Standard care plus compounds studied in the literature, organized by clinical readiness.
Treatment map: Bladder Cancer
Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works — confirm anything here with your oncology team.
36
Interventions
0
Standard of care
20
Tested in people
1
Lab / animal
13
Named in lit.
5
Classes
Tested in people, by trial phase: phase not reported ×20
Clinical evidence
Preclinical evidence
Standard of care
Guideline option
Tested in people
Lab / animal only
Named in the literature
Surgery & procedures
—
—
12
—
5
Chemotherapy
—
—
4
—
6
Targeted therapy
—
—
1
—
—
Immunotherapy
—
2
2
—
—
Other
—
—
1
1
2
Columns group into clinical evidence (used in, or tested on, people) and preclinical evidence (lab/animal, or only named in the literature). Cell = number of interventions; a dashed cell means none recorded there.
Established care — detail (2)
Investigational & adjunct compounds — detail (34)
Meta-analysis (20)
Named in the literature
Lab / animal only
"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA ✓" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.